S&P Futures
3,919.25-3.25(-0.08%)Dow Futures
31,948.00+32.00(+0.10%)Nasdaq Futures
13,245.25-56.75(-0.43%)
Chart Events
Performance Outlook
| Previous Close | 106.27 |
| Open | 106.00 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1100 |
| Day's Range | 105.60 - 109.44 |
| 52 Week Range | 62.55 - 113.41 |
| Volume | 6,594,042 |
| Avg. Volume | 7,363,890 |
| Market Cap | 191.934B |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | 39.96 |
| EPS (TTM) | 2.72 |
| Earnings Date | Apr 29, 2021 - May 03, 2021 |
| Forward Dividend & Yield | 5.20 (4.89%) |
| Ex-Dividend Date | Apr 14, 2021 |
| 1y Target Est | 120.67 |
Fair Value
Related Research
- PR Newswire
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical trials, HUMIRA induced clinical remission at Week 8 and maintained remission at Week 52 in patients who responded at Week 8.1,2
- CNW Group
AbbVie's SKYRIZI® for the Treatment of Moderate to Severe Plaque Psoriasis now Publicly Reimbursed across Canada
* SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe plaque psoriasis.1 * In clinical studies, SKYRIZI® significantly improved levels of skin clearance after just 16 weeks and maintained clearance at one year (52 weeks).
- Insider Monkey
Top 15 Pharmaceutical Companies With Highest R&D Spending
In this article we are going to list the top 15 pharmaceutical companies with the highest R&D spending. Click to skip ahead and jump to the Top 5 Pharmaceutical Companies With Highest R&D Spending. Pharma companies have always been among the most important companies in the world, even if they have been much maligned as […]
